Travellers Rabies Intra Dermal Later testing & boosting of blood antibodies

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12619000945123

Acronym

TRIDL

Enrollment

158

Registered

2019-07-05

Start date

2020-04-02

Completion date

2021-06-22

Last updated

2022-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The use of Intradermal (ID) rabies vaccine was described in 1976, with the promise of allowing cheaper protection from a disease, which has been feared throughout history. Although deaths in travellers are rare (60 reported cases 1990 – 2012 ), rabies risk exposures are relatively common (2-13/1000 travellers per month) In travellers who are aware the horrors of this untreatable disease, a potential rabies exposure can be stressful, and cause major disruption to travel plans in the quest for appropriate treatment. The standard Pre Exposure Rabies vaccination course (PrEP) of one dose ID vaccine on day 0,7,21-28 has been recommended for some time. A modified ID course of two doses of ID rabies vaccine on day 0, and 7 with one dose on day 21-28 has been documented in our clinic and published in 2011 [Mills et al. Journal of Travel Medicine. 2011;18(5):327–332]. This project aims to document the long term persistence and boostability of rabies antibodies in travellers who have had a course of ID rabies vaccine.

Interventions

Intradermal (deltoid) administration of a booster dose of 0.1ml of Merieux Inactivated Rabies Vaccine (lyophilised, stabilised suspension containing not less than 2.5 international units of inactivated Wistar rabies virus strain per 1ml) to participants that received a modified intradermal course of rabies vaccine more than 5 years ago

Study design

Allocation

Non-randomised trial

Primary purpose

Prevention

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Intradermal rabies course more than 5 years ago, and no further boosters during that time 2. Able to give written Informed Consent and sign consent after all aspects of the protocol explained 3. Subject must agree to receive a booster dose, have two blood tests and a planned follow-up telephone review. 4. Subjects need to be enrolled at least 14 days prior to departure

Exclusion criteria

1. Previous adverse reactions to rabies vaccine 2. Taking medications that impair the normal functioning of the immune system 3. Pregnancy or planning pregnancy

Outcome results